---
title: "Radiomics to Contextualize Biomarkers in Head and Neck Cancer Treatment Decisions"
id: "british-journal-of-cancer-0-radiomics-as-a-spatial-context-for-treatment-decision-making-in-head-and-neck"
canonical_url: "https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-radiomics-as-a-spatial-context-for-treatment-decision-making-in-head-and-neck"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "British Journal of Cancer"
source_url: "https://www.nature.com/articles/s41416-026-03600-0"
published_at: "2026-09-03T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Radiomics to Contextualize Biomarkers in Head and Neck Cancer Treatment Decisions
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-radiomics-as-a-spatial-context-for-treatment-decision-making-in-head-and-neck
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** British Journal of Cancer
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41416-026-03600-0)
- **Published At:** 2026-09-03T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Radiomics has been extensively investigated as a non-invasive imaging biomarker in **head and neck squamous cell carcinoma (HNSCC)** but its precise clinical role remains unresolved. - Tissue-based biomarkers vary in spatial stability: **PD-L1**, immune-cell infiltration, necrosis, and immune exclusion show substantial spatial heterogeneity, while **HPV/p16** status and some genomic alterations tend to be more spatially stable. - Localized biopsy sampling can miss important intratumoral heterogeneity, which may lead to non-representative biomarker-based treatment decisions in contexts such as chemoradiotherapy, immunotherapy, or de-escalation. - The authors propose that the primary role of **radiomics** is to provide spatial context for established biomarkers, not to replace them—capturing patterns related to **hypoxia**, necrosis, stromal architecture, and immune exclusion. - Existing evidence links specific radiomic features and phenotypes to biological processes (e.g., hypoxic or necrotic habitats) and maps these to clinical decision points including larynx preservation, immunotherapy stratification, and recurrence assessment. - Radiomics may flag situations where biopsy-derived biomarkers should be interpreted with caution by revealing spatial heterogeneity across intra- and peritumoral regions. - Most current evidence is retrospective; standardized radiomics methods and repeatability/reproducibility remain important considerations referenced in the literature (Image Biomarker Standardization Initiative, repeatability reviews). - The review presents conceptual radiomic phenotypes and a context-specific framework for interpreting radiomic signals across major HNSCC clinical scenarios while noting that radiomics offers a pragmatic approach to integrate spatial information into biomarker-guided workflows. - Data sharing is not applicable to this review because no new data were generated or analyzed in the article.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41416-026-03600-0#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![British Journal of Cancer](https://media.springernature.com/full/nature-cms/uploads/product/bjc/header-76ac17391903a21e28f15ff5df31f5fa.svg) ](https://www.nature.com/bjc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41416-026-03600-0) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/bjc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/bjc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/bjc/news-and-comment) * [ Current issue ](https://www.nature.com/bjc/current-issue) * [ Collections ](https://www.nature.com/bjc/collections) * [Follow us on X ](https://twitter.com/BrJCancer) * [ Subscribe ](https://www.nature.com/bjc/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41416) * [ RSS feed ](https://www.nature.com/bjc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Journal Information ](https://www.nature.com/bjc/journal-information) * [ Open access publishing ](https://www.nature.com/bjc/open-access) * [ About the Editors ](https://www.nature.com/bjc/editors) * [ Contact ](https://www.nature.com/bjc/contact) * [ Special Issues ](https://www.nature.com/bjc/special-issues) * [ For Advertisers ](https://www.nature.com/bjc/advertising) * [ Subscribe ](https://www.nature.com/bjc/subscribe) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors & Referees ](https://www.nature.com/bjc/authors-and-referees) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/bjc/open-access-funding) * [Submit manuscript ](https://mts-bjcancer.nature.com/) * [ Subscribe ](https://www.nature.com/bjc/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41416) * [ RSS feed ](https://www.nature.com/bjc.rss) 1. [nature](https://www.nature.com/) 2. [british journal of cancer](https://www.nature.com/bjc) 3. [review articles](https://www.nature.com/bjc/articles?type=review-article) 4. article * Review Article * Published: 03 September 2026 Clinical Study # Radiomics as a spatial context for treatment decision-making in head and neck cancer * [Takeyuki Kono](https://www.nature.com/articles/s41416-026-03600-0#auth-Takeyuki-Kono-Aff1) [ORCID: orcid.org/0009-0008-5792-3072](https://orcid.org/0009-0008-5792-3072)[1](https://www.nature.com/articles/s41416-026-03600-0#Aff1), * [Ken Kasahara](https://www.nature.com/articles/s41416-026-03600-0#auth-Ken-Kasahara-Aff1)[1](https://www.nature.com/articles/s41416-026-03600-0#Aff1), * [Ryo Ogawa](https://www.nature.com/articles/s41416-026-03600-0#auth-Ryo-Ogawa-Aff1)[1](https://www.nature.com/articles/s41416-026-03600-0#Aff1) & * … * [Hiroyuki Ozawa](https://www.nature.com/articles/s41416-026-03600-0#auth-Hiroyuki-Ozawa-Aff1)[1](https://www.nature.com/articles/s41416-026-03600-0#Aff1) Show authors [_British Journal of Cancer_](https://www.nature.com/bjc) (2026) [Cite this article](https://www.nature.com/articles/s41416-026-03600-0#citeas) [ Save article ](https://www.nature.com/articles/s41416-026-03600-0/save-research?_csrf=MM5W364ScLyzJjC7YOuq6XJCI74fS36Z) [ View saved research ](https://www.nature.com/saved-research) ## Abstract Radiomics has been widely explored as a non-invasive biomarker in head and neck squamous cell carcinoma (HNSCC), yet its clinical role remains unclear. Tissue-based biomarkers differ in their susceptibility to spatial sampling. Biomarkers such as PD-L1 expression, immune-cell infiltration, necrosis, and immune exclusion may exhibit substantial spatial heterogeneity, whereas HPV/p16 status and some genomic alterations are generally more stable across the tumor. Nevertheless, localized sampling may incompletely capture heterogeneity in selected clinical contexts. This mismatch becomes clinically relevant when treatment decisions, particularly for chemoradiotherapy, immunotherapy, or de-escalation, are based on potentially non-representative biopsy findings. In this narrative review, we argue that the role of radiomics is not to outperform established biomarkers, but to contextualize them by capturing spatial heterogeneity related to hypoxia, necrosis, stromal architecture, and immune exclusion. We synthesize current evidence linking radiomic features to these biological processes and map them to specific clinical decision points, including larynx preservation, immunotherapy stratification, and recurrence assessment. Rather than serving as a standalone predictor, radiomics may provide complementary spatial information that helps identify situations in which biopsy-derived biomarkers should be interpreted with caution. Although current evidence is largely retrospective, radiomics offers a pragmatic framework for integrating spatial information into biomarker-guided clinical workflows. ![](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41416-026-03600-0/MediaObjects/41416_2026_3600_Figa_HTML.png) This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41416-026-03600-0) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41416-026-03600-0) Subscribe to this journal Receive 24 print issues and online access 251,40 € per year only 10,48 € per issue [Learn more](https://www.nature.com/bjc/subscribe) Buy this article * Purchase on SpringerLink * Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/authorize/natureuser?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41416-026-03600-0) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) **Fig. 1: Conceptual radiomic phenotypes reflecting spatial heterogeneity in HNSCC.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41416-026-03600-0/MediaObjects/41416_2026_3600_Fig1_HTML.png) **Fig. 2: Context-specific framework for interpreting radiomic phenotypes across major clinical scenarios in HNSCC.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41416-026-03600-0/MediaObjects/41416_2026_3600_Fig2_HTML.png) ### Explore related subjects Discover the latest articles and news in related subjects. * [Head and neck cancer](https://www.nature.com/subjects/head-and-neck-cancer) * [Predictive markers](https://www.nature.com/subjects/predictive-markers) ## Data availability Data sharing is not applicable to this article as no new data were generated or analyzed. ## References 1. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11:9–22. [Article](https://doi.org/10.1038%2Fnrc2982) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhsFKlsrzK) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21160525) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20molecular%20biology%20of%20head%20and%20neck%20cancer&journal=Nat%20Rev%20Cancer&doi=10.1038%2Fnrc2982&volume=11&pages=9-22&publication_year=2011&author=Leemans%2CCR&author=Braakhuis%2CBJ&author=Brakenhoff%2CRH) 2. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92. [Article](https://doi.org/10.1056%2FNEJMoa1113205) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XktFOgtbw%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22397650) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878653) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Intratumor%20heterogeneity%20and%20branched%20evolution%20revealed%20by%20multiregion%20sequencing&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1113205&volume=366&pages=883-92&publication_year=2012&author=Gerlinger%2CM&author=Rowan%2CAJ&author=Horswell%2CS&author=Math%2CM&author=Larkin%2CJ&author=Endesfelder%2CD) 3. Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G Jr., et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–28. [Article](https://doi.org/10.1016%2FS0140-6736%2819%2932591-7) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXitV2ms7jM) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31679945) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20alone%20or%20with%20chemotherapy%20versus%20cetuximab%20with%20chemotherapy%20for%20recurrent%20or%20metastatic%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20%28KEYNOTE-048%29%3A%20a%20randomised%2C%20open-label%2C%20phase%203%20study&journal=Lancet&doi=10.1016%2FS0140-6736%2819%2932591-7&volume=394&pages=1915-28&publication_year=2019&author=Burtness%2CB&author=Harrington%2CKJ&author=Greil%2CR&author=Soulieres%2CD&author=Tahara%2CM&author=Castro%2CG) 4. Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr., Harrington KJ, et al. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019;25:5221–30. [Article](https://doi.org/10.1158%2F1078-0432.CCR-18-3944) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXltVegtL8%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31239321) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721346) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Nivolumab%20in%20Patients%20with%20Recurrent%20or%20Metastatic%20Squamous%20Cell%20Carcinoma%20of%20the%20Head%20and%20Neck%3A%20Efficacy%20and%20Safety%20in%20CheckMate%20141%20by%20Prior%20Cetuximab%20Use&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-18-3944&volume=25&pages=5221-30&publication_year=2019&author=Ferris%2CRL&author=Licitra%2CL&author=Fayette%2CJ&author=Even%2CC&author=Blumenschein%2CG&author=Harrington%2CKJ) 5. Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006. [Article](https://doi.org/10.1038%2Fncomms5006) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXitVShsb3L) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24892406) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059926) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Decoding%20tumour%20phenotype%20by%20noninvasive%20imaging%20using%20a%20quantitative%20radiomics%20approach&journal=Nat%20Commun&doi=10.1038%2Fncomms5006&volume=5&publication_year=2014&author=Aerts%2CHJ&author=Velazquez%2CER&author=Leijenaar%2CRT&author=Parmar%2CC&author=Grossmann%2CP&author=Carvalho%2CS) 6. Rai P, Mahajan A. Radiomics in head and neck squamous cell carcinoma - a leap towards precision oncology. J Immunother Cancer. 2025;13:e011692. [Article](https://doi.org/10.1136%2Fjitc-2025-011692) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=40274280) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020748) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Radiomics%20in%20head%20and%20neck%20squamous%20cell%20carcinoma%20-%20a%20leap%20towards%20precision%20oncology&journal=J%20Immunother%20Cancer&doi=10.1136%2Fjitc-2025-011692&volume=13&publication_year=2025&author=Rai%2CP&author=Mahajan%2CA) 7. Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749–62. [Article](https://doi.org/10.1038%2Fnrclinonc.2017.141) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28975929) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Radiomics%3A%20the%20bridge%20between%20medical%20imaging%20and%20personalized%20medicine&journal=Nat%20Rev%20Clin%20Oncol&doi=10.1038%2Fnrclinonc.2017.141&volume=14&pages=749-62&publication_year=2017&author=Lambin%2CP&author=Leijenaar%2CRTH&author=Deist%2CTM&author=Peerlings%2CJ&author=Jong%2CEEC&author=Timmeren%2CJ) 8. Zwanenburg A, Vallieres M, Abdalah MA, Aerts H, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328–38. [Article](https://doi.org/10.1148%2Fradiol.2020191145) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32154773) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193906) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20image%20biomarker%20standardization%20initiative%3A%20standardized%20quantitative%20radiomics%20for%20high-throughput%20image-based%20phenotyping&journal=Radiology&doi=10.1148%2Fradiol.2020191145&volume=295&pages=328-38&publication_year=2020&author=Zwanenburg%2CA&author=Vallieres%2CM&author=Abdalah%2CMA&author=Aerts%2CH&author=Andrearczyk%2CV&author=Apte%2CA) 9. Traverso A, Wee L, Dekker A, Gillies R. Repeatability and reproducibility of radiomic features: a systematic review. Int J Radiat Oncol Biol Phys. 2018;102:1143–58. [Article](https://doi.org/10.1016%2Fj.ijrobp.2018.05.053) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30170872) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690209) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Repeatability%20and%20reproducibility%20of%20radiomic%20features%3A%20a%20systematic%20review&journal=Int%20J%20Radiat%20Oncol%20Biol%20Phys&doi=10.1016%2Fj.ijrobp.2018.05.053&volume=102&pages=1143-58&publication_year=2018&author=Traverso%2CA&author=Wee%2CL&author=Dekker%2CA&author=Gillies%2CR) 10. van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77:e104–e7. [Article](https://doi.org/10.1158%2F0008-5472.CAN-17-0339) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29092951) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672828) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Computational%20radiomics%20system%20to%20decode%20the%20radiographic%20phenotype&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-17-0339&volume=77&pages=e104-e7&publication_year=2017&author=Griethuysen%2CJJM&author=Fedorov%2CA&author=Parmar%2CC&author=Hosny%2CA&author=Aucoin%2CN&author=Narayan%2CV) 11. Yuan Z, Ai S, He Q, Wu K, Yang M, Zheng K, et al. Intratumoral and peritumoral habitat radiomics of MRI predicts pathologic complete response to neoadjuvant chemoimmunotherapy in oral squamous cell carcinoma. Int J Surg. 2025;111:6232–44. [Article](https://doi.org/10.1097%2FJS9.0000000000002715) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=40540293) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12430773) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Intratumoral%20and%20peritumoral%20habitat%20radiomics%20of%20MRI%20predicts%20pathologic%20complete%20response%20to%20neoadjuvant%20chemoimmunotherapy%20in%20oral%20squamous%20cell%20carcinoma&journal=Int%20J%20Surg&doi=10.1097%2FJS9.0000000000002715&volume=111&pages=6232-44&publication_year=2025&author=Yuan%2CZ&author=Ai%2CS&author=He%2CQ&author=Wu%2CK&author=Yang%2CM&author=Zheng%2CK) 12. Marcu DC, Grava C, Marcu LG. Current role of delta radiomics in head and neck oncology. Int J Mol Sci. 2023;24:2214. [Article](https://doi.org/10.3390%2Fijms24032214) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXjsVSqtbs%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36768535) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916410) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Current%20role%20of%20delta%20radiomics%20in%20head%20and%20neck%20oncology&journal=Int%20J%20Mol%20Sci&doi=10.3390%2Fijms24032214&volume=24&publication_year=2023&author=Marcu%2CDC&author=Grava%2CC&author=Marcu%2CLG) 13. Trada Y, Keall P, Jameson M, Moses D, Lin P, Chlap P, et al. Changes in serial multiparametric MRI and FDG-PET/CT functional imaging during radiation therapy can predict treatment response in patients with head and neck cancer. Eur Radiol. 2023;33:8788–99. [Article](https://link.springer.com/doi/10.1007/s00330-023-09843-2) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37405500) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667402) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Changes%20in%20serial%20multiparametric%20MRI%20and%
## Related Clinical Research

- [Translational modelling questions receptor‑occupancy‑based dosing for pembrolizumab (PD‑1 inhibito](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-translational-modelling-challenges-receptor-occupancy-based-dosing-of-pd-1.md)
- [PD-L1 expression and survival in unresectable or recurrent gastric cancer treated with first-line](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-pd-l1-expression-and-survival-in-unresectable-recurrent-gastric-cancer-treated.md)
- [Temporal muscle thickness on head CT predicts immunotherapy response in head and neck squamous cel](https://medichelpline.com/clinical-feed/plos-one-11-temporal-muscle-thickness-is-associated-with-immunotherapy-outcomes-in-head-and.md)
- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Challenging FDA-Approved Cancer Drug Dosages: A Patient and Research Perspective](https://medichelpline.com/clinical-feed/kff-health-news-2-how-much-of-a-cancer-drug-is-too-much-patients-researchers-challenge-fda.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.